Condition
Type 2 Diabetes (T2D)
Locations
Greece, Japan, United States
Start date
07/08/2024
Identifiers
Trial ID
NN9490-7678,
NCT number NCT06542874,
Eudract number Not Available
NCT number NCT06542874,
Eudract number Not Available
Summary
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Trial Overview:
Treatment
DRUG: NNC0487-0111 subcutanous
DRUG: Placebo (NNC0487-0111 subcutanous)
DRUG: NNC0487-0111 oral
DRUG: Placebo (NNC0487-0111 oral)
Study type
INTERVENTIONAL
Trial duration
Aug 07 2024 - Oct 24 2025
Participants
432
Phase
II
Are you eligible?
Gender
Male and female
Age
18 to 75 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.